1-20 of 196
Matthew S. Davids
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Orally Bioavailable CDK9 Inhibitor Voruciclib Downregulates Oncogenic Pathways in Leukemic Cells from Patients Treated on a Clinical Trial

Edward C. Dominguez, Carly Roleder, Canping Chen, Zheng Xia, Sandra Wiley, Matthew S. Davids, Alexey Danilov
Journal: Blood
Blood (2024) 144 (Supplement 1): 721.
https://doi.org/10.1182/blood-2024-198693
Published: 2024
Journal Articles

Clonal Evolution during Dual B Cell Receptor Pathway Inhibitor Therapy with Acalabrutinib and Umbralisib in CLL Patients

Saurabh Yadav, Sumbul Jawed Khan, Binu Kandathilparambil Sasi, Elizabeth F. Cohen, Kiyomi Mashima, Hannah Cormier, Stacey M. Fernandes, Samantha J. Shupe, Roberta Santos Azevedo, Mariia Mikhaleva, Philippe Armand, David C. Fisher, Matthew S. Davids, Inhye E. Ahn, Michael Y. Tolstorukov, Mark A. Murakami, Jennifer R. Brown
Journal: Blood
Blood (2024) 144 (Supplement 1): 4611.
https://doi.org/10.1182/blood-2024-207527
Published: 2024
Journal Articles

Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL

James T. Yoon, Yinglu Zhou, Svitlana Tyekucheva, Mariia Mikhaleva, Stacey M. Fernandes, Philippe Armand, Amy C. Bessnow, Jennifer L. Crombie, David C. Fisher, Eric D. Jacobsen, Caron A. Jacobson, Austin I. Kim, Ann S. LaCasce, Reid W. Merryman, Oreofe O. Odejide, Erin M. Parry, David A. Qualls, Christine E. Ryan, Aswin Sekar, Jacob D. Soumerai, Jon E. Arnason, Matthew S. Davids, Jennifer R. Brown, Inhye E. Ahn
Journal: Blood
Blood (2024) 144 (Supplement 1): 4617.
https://doi.org/10.1182/blood-2024-199577
Published: 2024
Journal Articles

Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to Venetoclax

Matthew S. Davids, Sikander Ailawadhi, Asher A. Chanan-Khan, Boyd Mudenda, Larysa Nogaieva, Iryna Kryachok, Ganna Usenko, Vladimir Ivanov, Olena Kyselova, Tetiana Perekhrestenko, Ivan Muzhychuk, Alexander Myasnikov, Les Lukavetsky, Andrei Proydakov, Olga Uspenskaya, Elena Borisenkova, Paula Marlton, Tanya Siddiqi, Allison M. Winter, Tamila Lysa, Bulat Akhatovich Bakirov, Tommy Fu, Mingyu Li, Mohammad Ahmad, Zi Chen, Zhiyan Liang, Divya J. Mekala, Olena Karpenko, Iurii Osipov, Asit De, Hengbang Wang, Nashat Gabrail, Vinod Ganju, Tatiana Konstantinova, Olga Samoilova, Dajun Yang, Yifan Zhai
Journal: Blood
Blood (2024) 144 (Supplement 1): 4614.
https://doi.org/10.1182/blood-2024-207408
Published: 2024
Journal Articles

A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)

Jennifer L. Crombie, Christine E. Ryan, Yue Ren, Svitlana Tyekucheva, Celeste Carey, Aaron Zou, Samantha Normilus, Josie Montegaard, Jacob D. Soumerai, Shruti Bhandari, Jon E. Arnason, Alvaro J Alencar, Austin I. Kim, Erin M. Parry, Philippe Armand, David C. Fisher, Jennifer R. Brown, Matthew S. Davids
Journal: Blood
Blood (2024) 144 (Supplement 1): 4628.
https://doi.org/10.1182/blood-2024-199234
Published: 2024
Journal Articles

Treatment Outcomes of Patients Treated with Venetoclax-Obinutuzumab Therapy Vs Btki Therapies in 1L CLL: An International Real-World Study

Nicole Lamanna, Jennifer R. Brown, Chaitra S. Ujjani, Toby A. Eyre, Beenish Manzoor, Nilanjan Ghosh, Lindsey Roeker, Matthew S. Davids, Catherine C Coombs, Alan P Skarbnik, Brian T. Hill, Hande H. Tuncer, Lori A. Leslie, Joanna M. Rhodes, Isabelle Fleury, Paul M Barr, Nnadozie Emechebe, Nicolas Martinez-Calle, Christopher E. Jensen, Yun Choi, Dureshahwar Jawaid, Laurie K Pearson, Meghan C. Thompson, Steven E Marx, Wendy J. Sinai, Frederick Lansigan, Bita Fakhri, Deborah M. Stephens, Stephen J. Schuster, Michael Coyle, Irina Pivneva, Talissa Watson, Annie Guerin, Mazyar Shadman
Journal: Blood
Blood (2024) 144 (Supplement 1): 4625.
https://doi.org/10.1182/blood-2024-205223
Published: 2024
Journal Articles

Long-Term Follow-up of Bendamustine/Rituximab - Rituximab/Cytarabine (BR/RC) Induction Therapy for Previously Untreated Transplant-Eligible Patients with Mantle Cell Lymphoma (MCL)

Christine E. Ryan, Imran A. Nizamuddin, Hari S. Raman, Robert A. Redd, Marcus P. Watkins, Ann S. LaCasce, David C. Fisher, Austin I. Kim, Matthew S. Davids, Caron A. Jacobson, Oreofe O. Odejide, Jennifer L. Crombie, Neha Mehta-Shah, Amanda F. Cashen, Armin Ghobadi, Nancy L. Bartlett, Eric D. Jacobsen, Philippe Armand, Brad S. Kahl, Reid W. Merryman
Journal: Blood
Blood (2024) 144 (Supplement 1): 4409.
https://doi.org/10.1182/blood-2024-198687
Published: 2024
Journal Articles

Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)

Austin I. Kim, Philippe Armand, Christine E. Ryan, Robert A. Redd, Megan Forsyth, Juniper Mai, Samantha Pazienza, Caitlin Bresnahan, Vanessa M Kats, Salah Abdulkarim, Susan M Waisgerber, Reid W. Merryman, David C. Fisher, Inhye E. Ahn, Jennifer L. Crombie, Oreofe O. Odejide, Ann S. LaCasce, Caron A. Jacobson, Eric D. Jacobsen, Erin M. Parry, David A. Qualls, Amy C. Bessnow, Matthew S. Davids, Jennifer R. Brown, Jon E. Arnason, Michael Leukam, Peter A. Riedell, Mark A. Murakami
Journal: Blood
Blood (2024) 144 (Supplement 1): 4408.
https://doi.org/10.1182/blood-2024-198056
Published: 2024
Journal Articles

BRAVE: A Phase 2 Trial Evaluating the Efficacy and Safety of Venetoclax in Combination with Bruton's Tyrosine Kinase Inhibitors in Patients with First-Line Chronic Lymphocytic Leukemia

Matthew S. Davids, John M. Burke, Jennifer A. Woyach, Mina Shahkarami, Katherine Eakle, Jinnie Ko, Vivek S. Chopra, Weize Huang, Rona Farighi, Richard H. Ko, Jeff P. Sharman, William G. Wierda
Journal: Blood
Blood (2024) 144 (Supplement 1): 3257.2.
https://doi.org/10.1182/blood-2024-201555
Published: 2024
Journal Articles

Salinomycin Nanoparticles Induce Ferroptosis and Synergize with the BCL-2 Inhibitor Venetoclax to Promote AML Cell Death

Suiyang Liu, Wei Ni, Fen Zhu, Basudev Chowdhury, Ilene A. Galinsky, Matthew S. Davids, Ellen L Weisberg, Surender Kharbanda, Richard M. Stone
Journal: Blood
Blood (2024) 144 (Supplement 1): 5820.
https://doi.org/10.1182/blood-2024-203992
Published: 2024
Journal Articles

Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Matthew S. Davids, Christine E. Ryan, Yue Ren, Liam Hackett, Jeremy Zhang, Svitlana Tyekucheva, Stacey M. Fernandes, Jennifer L. Crombie, Austin I. Kim, Matthew Weinstock, Josie Montegaard, Heather A. Walker, Claire Greenman, Victoria Patterson, Caron A. Jacobson, Ann S. LaCasce, Philippe Armand, David C. Fisher, Steve Lo, Adam J. Olszewski, Jon E. Arnason, Inhye E. Ahn, Jennifer R. Brown
Journal: Blood
Blood (2024) 144 (Supplement 1): 1865.
https://doi.org/10.1182/blood-2024-206556
Published: 2024
Journal Articles

Low Variant Allele Frequency (VAF) TP53 Mutation (mut) Is Not a Poor Prognostic Marker in CLL Patients Treated with Targeted Therapy

Daniel Sungchul Choi, Yue Ren, Svitlana Tyekucheva, Stacey M. Fernandes, Mariia Mikhaleva, Kiyomi Mashima, Rayan Fardoun, Samantha J. Shupe, Stephen Martindale, Matthew S. Davids, Jennifer R. Brown, Inhye E. Ahn
Journal: Blood
Blood (2024) 144 (Supplement 1): 587.
https://doi.org/10.1182/blood-2024-208951
Published: 2024
Journal Articles

Ipilimumab with and without Nivolumab in Patients with Classic Hodgkin Lymphoma with Progression after PD-1 Blockade

Reid W. Merryman, Justin Kline, Robert A. Redd, Emma L. Welsh, Kathleen Pfaff, Hannah Juhaie Lee, Mikaela M. McDonough, Inhye E. Ahn, Jennifer R. Brown, Jennifer L. Crombie, Matthew S. Davids, David C. Fisher, Eric D. Jacobsen, Caron A. Jacobson, Austin I. Kim, Oreofe O. Odejide, Erin M. Parry, Christine E. Ryan, Margaret A. Shipp, Philippe Armand, Scott J. Rodig, Jeremy S. Abramson, Ann S. LaCasce
Journal: Blood
Blood (2024) 144 (Supplement 1): 1669.
https://doi.org/10.1182/blood-2024-203414
Published: 2024
Journal Articles

Complex Karyotype, but Not Isolated TP53 mutation, Predicts Overall Survival in Chronic Lymphocytic Leukemia Patients in the Era of Targeted Therapy

Roberta Santos Azevedo, Mariia Mikhaleva, Kiyomi Mashima, Stephen Martindale, Stacey M. Fernandes, Svitlana Tyekucheva, Inhye E. Ahn, Matthew S. Davids, Jennifer R. Brown
Journal: Blood
Blood (2024) 144 (Supplement 1): 583.
https://doi.org/10.1182/blood-2024-206576
Published: 2024
Journal Articles

Venetian: A Phase 2b/3 Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) and Optimize Initiation of Venetoclax (Ven) in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)

William G. Wierda, Matthew S. Davids, Jeff P. Sharman, Nilanjan Ghosh, Yang Feng, Mary Jean Fusco, Jacqueline Hilger-Rolfe, Chen Qian, Wendy J. Sinai, Sophie Wimberley, John F. Seymour
Journal: Blood
Blood (2024) 144 (Supplement 1): 6784.
https://doi.org/10.1182/blood-2024-207716
Published: 2024
Journal Articles

Comparative Assessment of Cell Line Models for Optimal Representation of Chronic Lymphocytic Leukemia

Salem Elias, Jeremy Zhang, Ritu Somayaji, Stephanie Chamberlain, Stephen Jun Fei Chong, Matthew S. Davids
Journal: Blood
Blood (2024) 144 (Supplement 1): 6759.
https://doi.org/10.1182/blood-2024-203777
Published: 2024
Journal Articles

Mechanistic Insights and Therapeutic Potential of a PRMT5 Inhibitor Combined with Venetoclax in B Cell Malignancies

Fen Zhu, Jing Wang, Christine E. Ryan, Liam Hackett, Jeremy Zhang, Stephen Jun Fei Chong, Matthew S. Davids
Journal: Blood
Blood (2024) 144 (Supplement 1): 1615.
https://doi.org/10.1182/blood-2024-205802
Published: 2024
Journal Articles

A Phase 2 Study of Zanubrutinib and Venetoclax (ZV) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Inhye E. Ahn, Yue Ren, David C. Fisher, Austin I. Kim, Nancy E. Kaddis, Jon E. Arnason, John P. Winters, III, Sobana Balasubramanian, Heather A. Walker, Victoria Patterson, Stacey M. Fernandes, Svitlana Tyekucheva, Matthew S. Davids, Jennifer R. Brown
Journal: Blood
Blood (2024) 144 (Supplement 1): 1874.
https://doi.org/10.1182/blood-2024-201668
Published: 2024
Journal Articles

Protein Degrader WH25244 Eliminates Venetoclax Resistance Factors: Mutant or Hyperphosphorylated BCL2, and BCL-XL

Daisy Y. Diaz Rohena, Andrew D. Mitchell, Jing Wang, Stephanie Chamberlain, Chaomei Liu, John R. Sanchez, II, Charmelle D. Williams, Trisha K. Wathan, Bailey Slawin, Kevin Bowman, Yaxia Yuan, Peiyi Zhang, Wanyi Hu, Guangrong Zheng, William G. Wierda, Nitin Jain, Matthew S. Davids, Daohong Zhou, Jennifer A. Woyach, Deepa Sampath
Journal: Blood
Blood (2024) 144 (Supplement 1): 2786.
https://doi.org/10.1182/blood-2024-208159
Published: 2024
Journal Articles

Pharmacodynamic Analysis of Mcl-1 and RNA Pol II Ser2 Phosphorylation in Blasts from Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated on a Phase 1 Study of Venetoclax Plus Voruciclib

Nathalie Javidi-Sharifi, Jeremy Zhang, Sandra Wiley, Richard G Ghalie, Alexey V. Danilov, Matthew S. Davids
Journal: Blood
Blood (2024) 144 (Supplement 1): 4147.
https://doi.org/10.1182/blood-2024-203689
Published: 2024